Tags

Type your tag names separated by a space and hit enter

CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Clin Cancer Res. 2003 Nov 01; 9(14):5318-24.CC

Abstract

PURPOSE

The purpose of this study was to investigate the expression and prognostic significance of CD44 in epithelial ovarian cancer.

EXPERIMENTAL DESIGN

We analyzed the expression of CD44 by immunohistochemistry in 307 epithelial ovarian cancers and evaluated its relation to hyaluronan, clinicopathological factors, and prognosis.

RESULTS

Fifty-one percent of the tumors had a high proportion of CD44-positive cells (i.e., >/==" BORDER="0">10%), and this high CD44 expression was significantly associated with cancer cell-associated hyaluronan, well-differentiated tumor, mucinous histological type, and early stage of the tumor. High CD44 expression predicted better 5-year overall survival (50% versus 22%) and recurrence-free survival (70% versus 34%) in the univariate analyses (P < 0.00005 for both). In the Cox multivariate analyses, the independent predictors of overall survival at 5 years were primary residual tumor (P < 0.0005), International Federation of Gynecologists and Obstetricians (FIGO) stage (P = 0.001), histological grade (P = 0.014), adjuvant chemotherapy (P = 0.004), and stromal hyaluronan level (P < 0.0005), but not CD44. However, the expression of CD44 (P = 0.04) and stromal hyaluronan (P = 0.005) were both independent predictors of recurrence-free survival at 5 years, together with the size of the primary residual tumor (P < 0.0005) and histological type (P = 0.043).

CONCLUSIONS

The relatively frequent ectopic expression of CD44 on ovarian cancer cells is thus related to well-differentiated, early-stage tumor and long survival of the patients. Thus, whereas CD44-expressing cancer cells may adhere and implant to the hyaluronan-positive mesothelium, at least in model systems, high expression of CD44 in the tumor does not bring about an unfavorable prognosis.

Authors+Show Affiliations

Department of Pathology and Forensic Medicine, University of Kuopio and Kuopio University Hospital, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14614016

Citation

Sillanpää, Sari, et al. "CD44 Expression Indicates Favorable Prognosis in Epithelial Ovarian Cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 9, no. 14, 2003, pp. 5318-24.
Sillanpää S, Anttila MA, Voutilainen K, et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res. 2003;9(14):5318-24.
Sillanpää, S., Anttila, M. A., Voutilainen, K., Tammi, R. H., Tammi, M. I., Saarikoski, S. V., & Kosma, V. M. (2003). CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 9(14), 5318-24.
Sillanpää S, et al. CD44 Expression Indicates Favorable Prognosis in Epithelial Ovarian Cancer. Clin Cancer Res. 2003 Nov 1;9(14):5318-24. PubMed PMID: 14614016.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CD44 expression indicates favorable prognosis in epithelial ovarian cancer. AU - Sillanpää,Sari, AU - Anttila,Maarit A, AU - Voutilainen,Kirsi, AU - Tammi,Raija H, AU - Tammi,Markku I, AU - Saarikoski,Seppo V, AU - Kosma,Veli-Matti, PY - 2003/11/14/pubmed PY - 2004/7/20/medline PY - 2003/11/14/entrez SP - 5318 EP - 24 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 9 IS - 14 N2 - PURPOSE: The purpose of this study was to investigate the expression and prognostic significance of CD44 in epithelial ovarian cancer. EXPERIMENTAL DESIGN: We analyzed the expression of CD44 by immunohistochemistry in 307 epithelial ovarian cancers and evaluated its relation to hyaluronan, clinicopathological factors, and prognosis. RESULTS: Fifty-one percent of the tumors had a high proportion of CD44-positive cells (i.e., >/==" BORDER="0">10%), and this high CD44 expression was significantly associated with cancer cell-associated hyaluronan, well-differentiated tumor, mucinous histological type, and early stage of the tumor. High CD44 expression predicted better 5-year overall survival (50% versus 22%) and recurrence-free survival (70% versus 34%) in the univariate analyses (P < 0.00005 for both). In the Cox multivariate analyses, the independent predictors of overall survival at 5 years were primary residual tumor (P < 0.0005), International Federation of Gynecologists and Obstetricians (FIGO) stage (P = 0.001), histological grade (P = 0.014), adjuvant chemotherapy (P = 0.004), and stromal hyaluronan level (P < 0.0005), but not CD44. However, the expression of CD44 (P = 0.04) and stromal hyaluronan (P = 0.005) were both independent predictors of recurrence-free survival at 5 years, together with the size of the primary residual tumor (P < 0.0005) and histological type (P = 0.043). CONCLUSIONS: The relatively frequent ectopic expression of CD44 on ovarian cancer cells is thus related to well-differentiated, early-stage tumor and long survival of the patients. Thus, whereas CD44-expressing cancer cells may adhere and implant to the hyaluronan-positive mesothelium, at least in model systems, high expression of CD44 in the tumor does not bring about an unfavorable prognosis. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/14614016/CD44_expression_indicates_favorable_prognosis_in_epithelial_ovarian_cancer_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=14614016 DB - PRIME DP - Unbound Medicine ER -